• Assay Search

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
      • New Drug Candidates
      • NDA/MAA-enabling Studies
      • Generic Drugs/Biosimilars
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • Phase I and ll Studies
      • Study Experience
      • In-hospital Beds
      • Cardiovascular Safety Services
      • Highly Automated ECG Core Lab
      • Metabolic Diseases
      • NAFLD/NASH
      • Belfast – Center of Excellence for Respiratory
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • AAHRPP Accreditation
      • Recruitment
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Clinical Data Sciences
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process – Internal Studies
      • Streamlined Data Flow Process – Multi-Site Studies
    • Global Bioanalytical Services
      • Assay Search
      • Small Molecule
      • Large Molecule
      • Biosimilars
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
    • Global Bioanalytical Services
  • Celerion Asia
  • Tobacco Risk Evaluation
    • Protocol Development and Data Interpretation
    • Global Clinical Research
    • Global Bioanalytical Services
    • Global Regulatory Services
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Studies
    • Data Management and Biometrics
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Customized Program Planning for Opening IND Study
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • Celerion Video Library
  • News & Events
    • Blog
    • Press Room
    • Conferences/Events
    • Clinical Discussion Forums
      • Past Clinical Discussion Forums
  • Participate in a Study
  • Careers
  • Celerion Science Newsletter 2018 Q2
  • Celerion Science Newsletter 2018 Q1
  • Celerion Science Newsletter 2017 Q4
  • Celerion Science Newsletter 2017 Q3
  • Celerion Science Newsletter 2017 Q2
  • Celerion Science Newsletter 2017 Q1
  • Celerion Science Newsletter 2016 Q3

Blog

Entering the NASH Race: Tips for Early Clinical Development

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that affects over 17 million Americans and this number is growing. NASH can lead to cirrhosis, end-stage liver disease, liver transplant and even hepatocellular carcinoma.  Therefore, the need for treatment for this … Continue reading →

Oct 2018

The Next Frontier of Pharmacology: Micro Drug Delivery

Injectable medication can be burdensome for the patient, causing pain and discomfort, and can contribute to compliance issues especially when chronic treatment is required. A promising and emerging area in pharmacology that may alleviate these obstacles is transdermal microneedle drug … Continue reading →

Jul 2018

Know Your Numbers Campaign

Know Your Numbers Campaign At Celerion, our community outreach does not only serve to inform the public about who we are and medical research opportunities, but we also use this time to give back to our community. In April 2016, … Continue reading →

Apr 2018

Prediabetes, the New Normal in Early Clinical Research

Prediabetes, the New Normal in Early Clinical Research There is a growing shift in inclusion criteria from healthy normal subjects to patient groups in early drug development. For programs with a chronic metabolic disease investigational product, prediabetes subject enrollment in … Continue reading →

Nov 2017

Supporting the Next Major Health Epidemic

Supporting the Next Major Health Epidemic Non-alcoholic fatty liver disease (NAFLD)/Non-alcoholic steatohepatitis (NASH) is viewed as the next major health epidemic and with no current anti-NASH medication on the market to treat this chronic disease; it is expected to place … Continue reading →

Aug 2016

For more information contact us

  • LinkedIn
  • YouTube
  • Twitter

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2019 Celerion | Web Design by Aradius Group